請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33185
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林亮音 | |
dc.contributor.author | Fang-Yu Wu | en |
dc.contributor.author | 吳芳瑜 | zh_TW |
dc.date.accessioned | 2021-06-13T04:28:21Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-27 | |
dc.identifier.citation | Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol. 1997;54(1):1-8.
2. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58(11):1685-1693.. 3. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother. 2006;40(1):83-95. 4. Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr. 2007;137(1 Suppl):183S-185S. 5. Yue P, Mak N, Cheng Y, et al. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chinese Medicine. 6. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen CJ. Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit. 2004;10(8):RA187-192. 7. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin. 2005;26(2):143-149. 8. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009;7(3):293-302. 9. Cho JY, Kim AR, Yoo ES, Baik KU, Park MH. Ginsenosides from Panax ginseng differentially regulate lymphocyte proliferation. Planta Med. 2002;68(6):497-500. 10. Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004;18(4):227-234. 11. Caudrillier A, Hurtel-Lemaire AS, Wattel A, et al. Strontium ranelate decreases receptor activator of nuclear factor-KappaB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor. Mol Pharmacol. 2010;78(4):569-576. 12. Dazzi F, Lymperi S, Horwood N, Marley S, Gordon MY, Cope AP. Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood. 2008;111(3):1173-1181. 13. Young NS. Aplastic anaemia. The Lancet. 1995;346:228-232. 14. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70. 15. Issaragrisil S. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107(4):1299-1307. 16. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518-523. 17. International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718-1721. 18. Marsh JCW. Management of acquired aplastic anaemia. Blood Reviews. 2005;19(3):143-151. 19. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519. 20. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100(4):1185-1191. 21. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003;21:713-758. 22. Zeng W, Chen G, Kajigaya S, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103(1):325-332. 23. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91(10):3582-3592. 24. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97(4):895-900. 25. Neal S. Young PSaRTC. Aplastic anemia. Current Opinion in Hematology. 2008;15:162-168. 26. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. British Journal of Haematology. 2009;147(1):43-70. 27. Kaminski ER, Hows JM, Goldman JM, Batchelor JR. Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens. Br J Haematol. 1990;76(3):401-405. 28. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91(10):3637-3645. 29. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236-1242. 30. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049-2054. 31. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931-1934. 32. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130-1135. 33. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008;111(9):4446-4455. 10.1182/blood-2007-08-019729. 34. Calado RT. Telomeres and marrow failure. Hematology. 2009:338-343. 35. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236-2243. 36. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8(6):450-458. 37. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008;88(2):557-579. 38. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43(2 Pt 1):405-413. 39. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science. 2007;315(5820):1850-1853. 40. Cao Y, Huschtscha LI, Nouwens AS, et al. Amplification of telomerase reverse transcriptase gene in human mammary epithelial cells with limiting telomerase RNA expression levels. Cancer Research. 2008;68(9):3115-3123. 41. Li W, Fu J, Wang F, Yu G, Wang Y, Zhang X. Distinct overexpression of Fas ligand on T lymphocytes in aplastic anemia. Cell Mol Immunol. 2004;1(2):142-147. 42. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. 2009;Chapter 7:Unit7 1. 43. Lugli E, Ferraresi R, Roat E, et al. Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leuk Res. 2009;33(1):140-150. 44. Lea NC, Orr SJ, Stoeber K, et al. Commitment point during G0-->G1 that controls entry into the cell cycle. Mol Cell Biol. 2003;23(7):2351-2361. 45. Wimer BM, Mann PL. Mitogen information summaries. Cancer Biother Radiopharm. 2002;17(5):569-597. 46. Buchkovich KJ, Greider CW. Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell. 1996;7(9):1443-1454. 47. Kanellopoulos JM, De Petris S, Leca G, Crumpton MJ. The mitogenic lectin from Phaseolus vulgaris does not recognize the T3 antigen of human T lymphocytes. Eur J Immunol. 1985;15(5):479-486. 48. Muul LM, Silvin C, James SP, Candotti F. Measurement of proliferative responses of cultured lymphocytes. Curr Protoc Immunol. 2008;Chapter 7:Unit 7 10 11-17 10 24. 49. Chen CH, Campbell PA, Newman LS. MTT colorimetric assay detects mitogen responses of spleen but not blood lymphocytes. Int Arch Allergy Appl Immunol. 1990;93(2-3):249-255. 50. Nishioka C, Ikezoe T, Jing Y, Umezawa K, Yokoyama A. DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. Immunology. 2008;124(2):198-205. 51. Bas A, Forsberg G, Hammarstrom S, Hammarstrom ML. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol. 2004;59(6):566-573. 52. Rea IM, McNerlan SE, Alexander HD. CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. Exp Gerontol. 1999;34(1):79-93. 53. Richter GH, Mollweide A, Hanewinkel K, Zobywalski C, Burdach S. CD25 blockade protects T cells from activation-induced cell death (AICD) via maintenance of TOSO expression. Scand J Immunol. 2009;70(3):206-215. 54. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104(4):1094-1099. 55. van Agthoven A, Terhorst C, Reinherz E, Schlossman S. Characterization of T cell surface glycoproteins T 1 and T 3 present on all human peripheral T lymphocytes and functionally mature thymocytes. Eur J Immunol. 1981;11(1):18-21. 56. Lopez-Gonzalez JS, Prado-Garcia H, Aguilar-Cazares D, Molina-Guarneros JA, Morales-Fuentes J, Mandoki JJ. Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer. 2004;43(3):275-283. 57. Kuo YC, Yang NS, Chou CJ, Lin LC, Tsai WJ. Regulation of cell proliferation, gene expression, production of cytokines, and cell cycle progression in primary human T lymphocytes by piperlactam S isolated from Piper kadsura. Mol Pharmacol. 2000;58(5):1057-1066. 58. Iacobelli M, Rohwer F, Shanahan P, Quiroz JA, McGuire KL. IL-2-mediated cell cycle progression and inhibition of apoptosis does not require NF-kappa B or activating protein-1 activation in primary human T cells. J Immunol. 1999;162(6):3308-3315. 59. Young HA. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res. 1996;16(8):563-568. 60. Tsai WJ, Chen YC, Wu MH, et al. Seselin from Plumbago zeylanica inhibits phytohemagglutinin (PHA)-stimulated cell proliferation in human peripheral blood mononuclear cells. J Ethnopharmacol. 2008;119(1):67-73. 61. Chebel A, Rouault JP, Urbanowicz I, et al. Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells. J Biol Chem. 2009;284(51):35725-35734. 62. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 2002;181-182:475-481. 63. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-1512. 64. Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev. 2001;101(8):2511-2526. 65. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10(7):699-703. 66. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102(10):3584-3586. 67. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136-142. 68. Feng Y, Wu J, Feng X, et al. Timing of apoptosis onset depends on cell cycle progression in peripheral blood lymphocytes and lymphocytic leukemia cells. Oncol Rep. 2007;17(6):1437-1444. 69. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80(2):131-137. 70. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998;91(7):2360-2368. 71. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci U S A. 1999;96(9):5147-5152. 72. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45(3):355-363. 73. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177-182. 74. Tuzuner N, Bennett JM. Reference standards for bone marrow cellularity. Leuk Res. 1994;18(8):645-647. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33185 | - |
dc.description.abstract | 美蔘公司研發出含稀有人參皂苷的中藥複方水溶液,MG-1複方,臨床上能提升再生不良性貧血(aplastic anemia,AA)的造血功能,但機制不明。再生不良性貧血為罕見的骨髓衰竭疾病,可依發生原因分為先天性和後天性兩大類,而全血球減少症(pancytopenia)為AA典型的症狀之一。治療方法有骨髓移植、免疫抑制藥物、支持性療法及雄性素等,其中僅骨髓移植能根治。由於大多數的病人給予免疫抑制藥物會有療效,因此多數AA被認為是自體免疫所導致;此外部分病人使用雄性素有效,被證實是經由調控端粒酶活性的機制所致。本研究利用裂殖素植物血凝素(phytohemagglutinin,PHA)刺激周邊血液單核細胞(peripheral blood mononuclear cell,PBMC),藉此探討MG-1複方對PBMCs的調控。首先,我們利用流式細胞儀及MTS方法偵測MG-1複方對靜止及PHA刺激之PBMCs的T細胞活化標記CD25表現與生長影響,結果顯示MG-1複方會抑制PHA刺激之PBMCs的生長,且CD3+細胞的CD25表現下降。進一步分析細胞週期的變化,顯示MG-1複方使PHA刺激之PBMCs的細胞週期停滯於G0/G1時期。而Annexin V方法及Sub-G1分析皆顯示MG-1複方亦會使PHA刺激之PBMCs凋亡比例上升。由於介白素-2 (interleukin-2,IL-2)及干擾素-γ (interferon-γ,IFN-γ)在活化T細胞的生長中扮演重要的角色,本研究以即時聚合酶鏈鎖反應偵測IL-2及IFN-γ mRNA的表現,結果顯示兩者皆受到抑制。另一方面,以即時聚合酶鏈鎖反應偵測端粒酶(Telomerase,TERT) mRNA的表現及端粒酶活性,顯示MG-1複方對TERT mRNA的調控有個體差異,然而,對於端粒酶活性則無明顯影響。本研究顯示MG-1複方會導致PHA刺激之PBMCs的細胞週期停滯,進而抑制PHA刺激之PBMCs的生長,且會使PHA刺激之PBMCs凋亡比例增加,並抑制IL-2及IFN-γ mRNA的表現。 | zh_TW |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:28:21Z (GMT). No. of bitstreams: 1 ntu-100-R98424011-1.pdf: 1633672 bytes, checksum: 27dd0582f8cc84fb7f9b40b1abd2cd8b (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書
誌謝 I 目錄 II 圖目錄 III 表目錄 III 縮寫表 IV 中文摘要 V 英文摘要 VII 第一章 前言 1 第二章 研究目的 9 第三章 實驗材料與方法 10 第四章 實驗結果 22 第五章 討論 28 第六章 結論 32 圖 33 表 48 參考文獻 51 附錄 61 圖目錄 圖一、PHA對PBMCs生長之影響 34 圖二、MG-1複方對PBMCs生長之影響 35 圖三、MG-1複方對T細胞活化標誌CD25的表現之影響 36 圖四、PHA對PBMCs細胞週期之影響 37 圖五、MG-1複方對PBMCs細胞週期之影響 39 圖六、MG-1複方對PBMCs細胞凋亡之影響 42 圖七、MG-1複方對PBMCs細胞激素IL-2 mRNA表現之影響 43 圖八、MG-1複方對PBMCs細胞激素IFN-γ mRNA表現之影響 44 圖九、PHA對PBMC端粒酶基因TERT、TERC mRNA及端粒酶活性之影響 45 圖十、MG-1複方對PBMCs端粒酶基因TERT mRNA表現之影響 46 圖十一、MG-1複方對PBMCs端粒酶活性之影響 47 表目錄 表一、再生不良性貧血嚴重程度之定義 49 表二、即時監控聚合酶連鎖反應所使用之引子與引子/探針 50 | |
dc.language.iso | zh-TW | |
dc.title | MG-1複方對周邊血液單核細胞作用之探討 | zh_TW |
dc.title | Exploring the Effect of MG-1 on Peripheral Blood Mononuclear Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林淑萍,楊雅倩,呂健惠,顧雅真 | |
dc.subject.keyword | MG-1,植物血凝素,周邊血液單核細胞,再生不良性貧血,端粒酶, | zh_TW |
dc.subject.keyword | MG-1,phytohemagglutinin (PHA),peripheral blood mononuclear cell (PBMC),aplastic anemia (AA),telomerase, | en |
dc.relation.page | 65 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。